Company / Free Cash Flow per Share
CytomX Therapeutics, Inc. Free Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow per Share
-$0.55
FY2025
5-year range
-$1.84 / -$0.55
FY2021-FY2025
Trend
+49.1%
vs FY2024
Sector context
#92 of 192
Health Care
What the data says
At $-0.55, CytomX Therapeutics, Inc.'s free cash flow per share ranks #92 of 192 in the Health Care sector. Free Cash Flow per Share has fluctuated over the past 10 years, ranging from $-3.16 in FY2019 to $4.39 in FY2017.
Based on SEC 10-K filings.
-0.55 in FY2025.
Improved from $-0.84 to $-0.55 over the past 2 years.
Health Care sector context is included.
Free Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#92 of 192 in Health CareTop 48% of 192This company -$0.55 Sector average -$19.84
▼
+97.2% above sector average
Key checks
Key Insights
- In FY2025, free cash flow per share increased 49.1% year-over-year.
- Ranks #92 out of 192 companies in the Health Care sector.
- Peak free cash flow per share was recorded in FY2017.
- Lowest free cash flow per share in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.55 | +49.1% |
| FY2024 | -$1.08 | -27.9% |
| FY2023 | -$0.84 | +50.3% |
| FY2022 | -$1.70 | +7.9% |
| FY2021 | -$1.84 | -2946.9% |
| FY2020 | $0.06 | +102.0% |
| FY2019 | -$3.16 | -79.8% |
| FY2018 | -$1.76 | -140.1% |
| FY2017 | $4.39 | +3904.4% |
| FY2016 | -$0.12 | +98.7% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026